Livestock Immunity Strategic partnerships with Novus International to co-develop feed solutions aimed at immunity health and reducing respiratory challenges in pigs indicate a clear sales opportunity to the animal health and livestock nutrition markets.

Microbiome Therapeutics Focus on non-antibiotic, microbiome-based therapeutics for respiratory infections across human and animal health presents a differentiated value proposition for buyers seeking alternatives to traditional antibiotics in both clinical and production settings.

Innovative Platform Proprietary discovery platform combining high-resolution genomics, in-house machine learning, and targeted in vitro assays can be leveraged to shorten development timelines and offer customized microbiome-derived strains to partner companies and CROs.

Leadership & Talent Key hires in bioinformatics and translational medicine, plus a small but focused team, suggest agility and potential for rapid on-boarding of clients, collaborators, and pilot programs with fast-path to translational outcomes.

Growth Funding Moderate revenue range with strategic funding and active partnerships positions Resilient Biotics as a scalable partner for co-development deals, licensing opportunities, and joint ventures in both feed solutions for animals and human health pipelines.